A multi-dose Phase 1b to evaluate the tolerability and PK profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT tablets
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2017
At a glance
- Drugs ADS 4101 (Primary) ; Lacosamide (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- 07 Sep 2017 Topline data presented in an Adamas Pharmaceuticals media release.
- 30 May 2017 New trial record
- 22 May 2017 According to an Adamas Pharmaceuticals media release, topline data from this study are expected in the third quarter of 2017.